Tamoxifen and Melatonin for Metastatic Tumors
Author Information
Author(s): P Lissoni, F Paolorossi, G Tancini, A Ardizzoni, S Barni, F Brivio, GJM Maestroni, M Chilelli
Primary Institution: Divisione di Radioterapia, Locarno, Switzerland; Oncologica, San Gerardo Hospital, Monza, Milan, Italy
Hypothesis
Can the combination of tamoxifen and melatonin enhance anti-tumor efficacy in metastatic solid tumor patients?
Conclusion
The combination of tamoxifen and melatonin may provide some benefit in controlling cancer cell proliferation and improving performance status in untreatable metastatic solid tumor patients.
Supporting Evidence
- Three patients had a partial response, and thirteen had stable disease.
- Performance status improved in 9 out of 25 patients.
- Survival longer than 1 year was observed in 7 out of 25 patients.
Takeaway
This study tested a new treatment using two drugs, tamoxifen and melatonin, to help patients with hard-to-treat cancers feel better and possibly slow down their cancer.
Methodology
Patients received tamoxifen and melatonin orally until disease progression, with clinical responses evaluated through radiological staging and laboratory tests.
Limitations
The small sample size and diverse tumor types limit the ability to draw definitive conclusions.
Participant Demographics
Median age was 64 years, with a male-to-female ratio of 10:15.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% confidence limits 2-24%
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website